However, the results show that PEG linker-based AuNVs were significantly more effective at stimulating CTLs.
Exosomes from the plasma of NPC patients were significantly more potent in stimulating tube‐forming capacity of HUVECs (Fig. 2f).
Primary prostate epithelial cells had a weaker effect on the BMECs, inducing fewer endothelial cells to invade towards TCP, with only BPH cells stimulating significantly more endothelial cells to invade (73±8 vs 34±11; P=0.037) than the no prostate epithelial cells control.
We found that cell-yeast interactions occurred in 21.9 ± 3.0% of control peptide-stimulated BV-2 cells, but that Aβ peptides stimulated significantly more such interactions (37.2 ± 2.8% and 41.0 ± 3.2%, Aβ40 versus Aβ42, respectively, p < 0.05, Fig. 6a, b).
MDDCs pulsed with HIV-1 stimulated significantly more CD4+ than CD8+ T cell responses.
Interestingly, muromonab-CD3 stimulated significantly more IL-1β (P = 0.0073) and IL-10 (P < 0.0001) release than TGN1412 (Table 6).
TGN1412 stimulated significantly more IL-2 release compared with muromonab-CD3 (P < 0.0001 at 24, 48 and 72 h).
Better management and administration of the Programme would have produced significantly more positive results and stimulated keener interest and engagement on the part of the MoEs.
Alemtuzumab and muromonab-CD3 stimulated significantly more CD4− cells that produced IFNγ (P = 0.0014 and P = 0.0115, respectively), compared with TGN1412.
However, TGN1412 stimulated significantly more CD4+ T-cells that produced IL-2 (P = 0.0001), IL-17 (P = 0.0008) and IFNγ (P = 0.0309) compared with muromonab-CD3.
Likewise, TGN1412 stimulated significantly more (P = 0.0001) IL-2 producing CD4+ T-cells than muromonab-CD3 and induced Th1, Th2, Th17 and Th22 subsets that co-release this cytokine.
